Abstract:Summary1. Cisplatin is a potent chemotherapeutic agent with broad‐spectrum antineoplastic activity against various types of tumours. However, a major factor limiting treatment with cisplatin is its acute and cumulative cardiotoxicity. The aim of the present study was to explore the effect of cisplatin on myocardial contractile function and the possible underlying cellular mechanisms.2. C57 mice were treated with cisplatin (10 mg/kg per day, i.v.) or vehicle (0.9% NaCl) for 1 week and myocardial function was assessed using the Langendorff and cardiomyocyte edge‐detection systems. Transmission electron microscopy, mitochondrial membrane potential, indices of endoplasmic reticulum (ER) stress and caspase 3 activity were evaluated.3. Cisplatin‐treated mice developed myocardial contractile dysfunction, as evidenced by a reduction in left ventricular developed pressure (LVDP) and the first derivative of LVDP (+/−dP/dt). Cisplatin treatment significantly prolonged time to 90% relengthening, depressed peak shortening, maximal velocity of shortening/relengthening (+/−dL/dt) and augmented the frequency‐elicited depression in peak shortening. The JC‐1 fluorescent assay demonstrated that cispatin‐induced cardiac dysfunction was associated with mitochondrial membrane depolarization. Transmission electron microscopy revealed that cisplatin induces ultrastructural abnormalities of the mitochondria. Following cisplatin treatment, cardiomyocytes show activation of the ER stress response, increased caspase 3 activity and increased terminal deoxyribonucleotidyl transferase‐mediated dUTP–digoxigenin nick end‐labelling (TUNEL) staining.4. The data indicate that cisplatin is cardiotoxic and may lead to left ventricular dysfunction and depressed cardiomyocyte contraction associated with mitochondrial abnormalities, enhanced ER stress and apoptosis. This work should shed some light on the management of cisplatin‐induced cardiac injury.

Research progress on cardiotoxicity induced by cisplatin

Advances in Toxicological Research of the Anticancer Drug Cisplatin

Pyrocatechol Alleviates Cisplatin-Induced Acute Kidney Injury by Inhibiting ROS Production

Research progress on the mechanisms of cisplatin-induced hepatotoxicity

Molecular mechanisms involved in therapeutic effects of natural compounds against cisplatin-induced cardiotoxicity: a review

Resveratrol Protects Against Cisplatin-Induced Cardiotoxicity by Alleviating Oxidative Damage

Research progress of cardiotoxicity induced by chemotherapeutic drugs

An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures

Clinical insights into cisplatin-induced arrhythmia in a patient with locally advanced non-small cell lung cancer: a case report

Cisplatin-induced Cardiotoxicity with Midrange Ejection Fraction A Case Report and Review of the Literature

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Cisplatin Compromises Myocardial Contractile Function and Mitochondrial Ultrastructure: Role of Endoplasmic Reticulum Stress

Activation of STING Pathway Contributed to Cisplatin-Induced Cardiac Dysfunction Via Promoting the Activation of TNF-α-AP-1 Signal Pathway

An integrated view of cisplatin-induced nephrotoxicity, hepatotoxicity, and cardiotoxicity: characteristics, common molecular mechanisms, and current clinical management

Cisplatin-induced Cardiotoxicity with Midrange Ejection Fraction

Cisplatin nephrotoxicity: new insights and therapeutic implications

Research progress of cardiotoxicology of anthracycline chemotherapeutics

Quercetin Mitigates Cisplatin-Induced Oxidative Damage and Apoptosis in Cardiomyocytes through Nrf2/HO-1 Signaling Pathway

Research progress on the premature ovarian failure caused by cisplatin therapy

Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies

Protective Effect of Natural Antioxidants on Reducing Cisplatin-Induced Nephrotoxicity.